Search Results for

SGNTUC-016

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Continue Reading »

---

BR004

Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

Continue Reading »

---

A171601

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Continue Reading »

---

S1703

Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Continue Reading »

---

BR002 (Suspended)

Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer (Suspended)

Continue Reading »

---

Search Again

• All Trial Categories Anal  (3) Bladder/Urinary Tract Cancer  (8)    Adjuvant  (1)    Metastatic  (2)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (5)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (5)    Breast Cancer Neoadjuvant  (1)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (21) Carcinoid Tumors  (2) Colorectal Cancer  (9)    Metastatic  (4) Esophageal Cancer  (2) Gastric Cancer  (2)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (4)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (5)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (3) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (24)    Non-Small Cell Lung Cancer  (18)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (4)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (3)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (6)       Extensive Stage SCLC  (3) Lymphoma  (8)    Non-Hodgkin’s Lymphoma  (4)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (3)          Relapsed/Refractory  (3) MATCH Trial  (1) MDS  (3) Melanoma  (7)    Metastatic  (3) Merkel Cell Carcinoma  (1) Multiple Myeloma  (1) Pancreatic  (6)    Metastatic Disease  (4) Prostate  (8) Renal Cell/Kidney Cancer  (6)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)